A Phase II Study to Determine the Antitumor Activity of Farnesyltransferase Inhibitor R115777 in Subjects With Relapsed Small Cell Lung Cancer
OBJECTIVES: I. Determine the objective response rate (complete or partial) and duration of
response of patients with small cell lung cancer who have had at least a partial response to
one prior chemotherapy regimen for at least 3 months when treated with R115777. II.
Determine the time to disease progression, survival, and quality of life in this patient
population treated with this drug. III. Assess the safety of R115777 in this patient
population. IV. Assess the presence of ras mutations in relapsed patients with available
OUTLINE: This is a multicenter study. Patients receive oral R115777 every 12 hours for 14
consecutive days followed by 7 days of rest. Treatment continues in the absence of
unacceptable toxicity or disease progression. Quality of life is assessed at baseline, on
day 15 of each course, and at the end of the study.
PROJECTED ACCRUAL: A total of 27-40 patients will be accrued for this study.
Primary Purpose: Treatment
Abraham Chachoua, MD
New York University School of Medicine
United States: Federal Government
|Kaplan Cancer Center||New York, New York 10016|